Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-04-17
2010-02-23
Gamett, Daniel C (Department: 1647)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S006120, C435S069100
Reexamination Certificate
active
07667020
ABSTRACT:
The present invention provides novel isolated BFLP1698 polynucleotides and polypeptides encoded by the BFLP1698 polynucleotides. Also provided are the antibodies that immunospecifically bind to a BFLP1698 polypeptide or any derivative (including fusion derivative), variant, mutant or fragment of the BFLP1698 polypeptide, polynucleotide or antibody. The invention additionally provides methods in which the BFLP1698 polypeptide, polynucleotide and antibody are utilized in the detection and treatment of a broad range of pathological states, as well as to other uses.
REFERENCES:
patent: WO 02/059260 (2002-08-01), None
PCT International Search Report; PCT/US03/37317; mailed Jan. 6, 2005, 6 pages.
Balow et al.,New Prospects For Treatment of Lupus Nephritis, Seminars in Nephrology, vol. 20, No. 1, pp. 32-39, 2000.
Davis et al.,Lupus Nephritis, Current Opinion in Rheumatology, vol. 8, No. 5, pp. 415-423, 1996.
Mercadal et al.,Lupus Nephritis, A Review of the Current Pharmacological Treatments, Expert Opinion Pharmacother., vol. 5, No. 11, pp. 2263-2277, 2004.
Rahman et al.,A Novel Susceptibility Locus On Chromosone 2 in the(New Zealand Black x New Zealand White)F1Hybrid Mouse Model of Systematic Lupus Erythematosus, The Journal of Immunology, vol. 168, No. 6, pp. 3042-3049, 2002.
BP Tsao,Genetic Susceptibility of Lupus Nephritis, Lupus, vol. 7, No. 9, pp. 585-590, 1998.
Database Geneseq Online Feb. 25, 2003, “Human protein SEQ ID 521,” XP002350892, retrieved from EBI accession No. GSN: ABP64861 Database accesion No. ABP64861.
Database UniProt Online May 1, 2000, XP002350893 retrieved from EBI Database accession No. Q9VFS6.
Database UniProt Online Mar. 1, 2003, XP002350894 retrieved from EBI Database accession No. Q8CHT3.
European Search Report for Application No. 03786989.8 (PCT/US03/37317) dated Nov. 11, 2005, 5 pages.
Vilella-Bach et al., “The FKBP12-Rapamycin-binding Domain Is Required for FKBP12-Rapamycin-associated Protein Kinase Activity and G1 Progression,”Journal of Biological Chemistry, 274(7):4266-4272 (1999).
Mounts William Martin
O'Toole Margot
Shojaee Negin
Gamett Daniel C
Hurley Elizabeth A.
Restrepo-Hartwig Maria
Wyeth
LandOfFree
Composition and method for treating lupus nephritis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for treating lupus nephritis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for treating lupus nephritis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4158193